The study introduces a novel "multi-route" administration protocol for Wharton’s Jelly-derived Mesenchymal Stem Cells (WJ-MSCs). Unlike previous trials that relied on a single delivery method, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback